Identification
NameSulfasalazine
Accession NumberDB00795  (APRD00152, DB08518)
TypeSmall Molecule
GroupsApproved
Description

A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)

Structure
Thumb
Synonyms
2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid
2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid
4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene
5-((P-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid
5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid
5-(P-(2-Pyridylsulfamyl)phenylazo)salicylic acid
Azopyrin
Salazosulfapiridina
Salazosulfapyridine
Salazosulfapyridinum
Salicylazosulfapyridine
Sulfasalazin
Sulfasalazina
Sulfasalazine
Sulfasalazinum
External IDs NSC-203730 / NSC-667219 / SSZ
Product Ingredients Not Available
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AzulfidineTablet500 mg/1OralPharmacia & Upjohn Inc1950-06-20Not applicableUs
Azulfidine EN-tabsTablet, delayed release500 mg/1OralPharmacia & Upjohn Inc1950-06-20Not applicableUs
Orb-sulfasalazine ECTablet, delayed release500 mgOralOrbus Pharma IncNot applicableNot applicableCanada
PMS-sulfasalazine 500mg/tab USPTablet500 mgOralPharmascience Inc1984-12-31Not applicableCanada
PMS-sulfasalazine-E.C. Tab 500mgTablet, delayed release500 mgOralPharmascience Inc1984-12-31Not applicableCanada
Ratio-sulfasalazine EnTablet, delayed release500 mgOralRatiopharm Inc Division Of Teva Canada Limited1986-12-312008-08-01Canada
Ratio-sulfasalazine Tab 500mgTablet500 mgOralRatiopharm Inc Division Of Teva Canada Limited1986-12-312008-08-01Canada
S.A.S. Enteric 500mgTablet, delayed release500 mgOralIcn Pharmaceuticals1979-12-312005-04-26Canada
Salazopyrin En-tabs 500 mgTablet, delayed release500 mgOralPfizer1995-12-31Not applicableCanada
Salazopyrin Enema 3.0gm/100mlSuspension3 gRectalKabi Pharmacia Canada Inc.1994-12-311996-09-10Canada
Salazopyrin Enema 3gm/100mlEnema3 gRectalPfizer1996-12-312006-08-02Canada
Salazopyrin Tab 500mgTablet500 mgOralPfizer1995-12-31Not applicableCanada
Sas Enema 3gm/100mlEnema3 gRectalIcn Pharmaceuticals1984-12-312005-04-26Canada
Sas Tab 500mgTablet500 mgOralIcn Pharmaceuticals1973-12-312005-04-26Canada
SulfasalazineTablet500 mg/1OralKaiser Foundations Hospitals2015-04-07Not applicableUs
SulfasalazineTablet500 mg/1OralA S Medication Solutions2003-07-012017-06-20Us
SulfasalazineTablet500 mg/1OralAvera Mc Kennan Hospital2015-03-17Not applicableUs
SulfasalazineTablet500 mg/1OralA S Medication Solutions2003-07-01Not applicableUs
SulfasalazineTablet500 mg/1OralMajor2000-08-18Not applicableUs
SulfasalazineTablet, delayed release500 mg/1OralGreenstone, Llc2005-05-05Not applicableUs59762 0104 01 nlmimage10 f83efc07
SulfasalazineTablet500 mg/1OralAphena Pharma Solutions Tennessee, Inc.2003-07-01Not applicableUs
SulfasalazineTablet500 mg/1OralGreenstone, Llc2003-07-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Sulfasalazine Tab 500mgTablet500 mgOralApotex Corporation1978-12-31Not applicableCanada
SulfasalazineTablet500 mg/1OralRemedy Repack2013-01-08Not applicableUs
SulfasalazineTablet500 mg/1OralActavis Pharma Company1982-10-01Not applicableUs
SulfasalazineTablet500 mg/1OralRemedy Repack2010-11-152016-10-13Us
SulfasalazineTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2002-01-112019-07-31Us
SulfasalazineTablet500 mg/1OralRemedy Repack2011-11-182017-08-04Us
SulfasalazineTablet500 mg/1OralPreferreed Pharmaceuticals Inc.2010-06-09Not applicableUs
SulfasalazineTablet500 mg/1OralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs00603 5801 28 nlmimage10 8f4547aa
SulfasalazineTablet500 mg/1OralRemedy Repack2017-01-30Not applicableUs
SulfasalazineTablet500 mg/1OralRemedy Repack2011-04-192016-10-13Us
SulfasalazineTablet500 mg/1OralQualitest2002-01-11Not applicableUs
SulfasalazineTablet500 mg/1OralAidarex Pharmaceuticals LLC2002-01-11Not applicableUs
SulfasalazineTablet500 mg/1Oralbryant ranch prepack1982-10-01Not applicableUs
SulfasalazineTablet500 mg/1OralA S Medication Solutions1982-10-012017-06-20Us
SulfasalazineTablet500 mg/1OralAv Pak2014-01-14Not applicableUs00591 0796 05 nlmimage10 580eac35
Sulfasalazine Delayed-ReleaseTablet, delayed release500 mg/1OralQualitest2002-01-11Not applicableUs00603 5803 25 nlmimage10 550eaa85
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AsasurfanChoseido Pharmaceutical
AzulfdidinaPfizer
AzulfidineNot Available
AzulfinApsen
BomeconFu Seng
Colo-PleonSanofi-Aventis
DisalazinAC Farma
EminapyrinTaiyo Pharmaceutical
FlogostopIvax
IwataCadila
LanofenTaisho Yakuhin
LazafinNovell
PleonSanofi-Aventis
Pyralin ENPfizer
ReumazinAristopharma
SaazIpca
Saaz-DSIpca
SalasopyrineUpjohn
SalazarCadila
SalazidinHelcor
SalazineOpsonin
SalazopirinaJaba Recordati
SalazoprinCazi
SalazopyrinPfizer
Salazopyrin ENPfizer
Salazopyrin EN-TabsPharmacia
SulcolonBernofarm
SulfacolDrug International
WeiliufenSunve
ZopyrinHan Lim
Brand mixturesNot Available
Categories
UNII3XC8GUZ6CB
CAS number599-79-1
WeightAverage: 398.393
Monoisotopic: 398.068490268
Chemical FormulaC18H14N4O5S
InChI KeyNCEXYHBECQHGNR-QZQOTICOSA-N
InChI
InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
IUPAC Name
2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid
SMILES
OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1
Pharmacology
Indication

For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.

Structured Indications
Pharmacodynamics

Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis.

Mechanism of action

The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitro models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown.

TargetKindPharmacological actionActionsOrganismUniProt ID
Arachidonate 5-lipoxygenaseProteinyes
inhibitor
HumanP09917 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Peroxisome proliferator-activated receptor gammaProteinyes
agonist
HumanP37231 details
Inhibitor of nuclear factor kappa-B kinase subunit alphaProteinunknown
inhibitor
HumanO15111 details
Inhibitor of nuclear factor kappa-B kinase subunit betaProteinunknown
inhibitor
HumanO14920 details
Cystine/glutamate transporterProteinunknown
inhibitor
HumanQ9UPY5 details
Acetyl-CoA acetyltransferase, mitochondrialProteinunknown
inhibitor
HumanP24752 details
Thromboxane-A synthaseProteinunknown
antagonist
HumanP24557 details
Phospholipase A2Proteinunknown
antagonist
HumanP04054 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 7.5 ± 1.6 L
Protein bindingNot Available
MetabolismNot Available
Route of elimination

The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces.

Half life

5-10 hours

Clearance
  • 1 L/h [IV administration]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Arylamine N-acetyltransferase 1NAT1*14ANot AvailableG > A | T > A | C > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 1NAT1*14BNot AvailableG > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 1NAT1*15Not AvailableC > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 1NAT1*17Not AvailableC > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 1NAT1*19ANot AvailableC > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 1NAT1*19BNot AvailableC > T | C > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 1NAT1*22Not AvailableA > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5ANot AvailableT > C | C > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5BNot AvailableT > C | C > T | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5CNot AvailableT > C | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5DNot AvailableT > C ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5ENot AvailableT > C | G > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5FNot AvailableT > C | C > T | C > T | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5GNot AvailableT > C | C > T | C > T | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5HNot AvailableT > C | C > T | A > G | S287 Frameshift ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5INot AvailableT > C | C > T | A > T | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*5JNot AvailableT > C | C > T | G > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*6ANot AvailableG > A | C > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*6BNot AvailableG > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*6CNot AvailableG > A | C > T | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*6DNot AvailableG > A | C > T | T > C ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*6ENot AvailableG > A | C > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*7ANot AvailableG > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*7BNot AvailableG > A | C > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*10Not AvailableG > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*12DNot AvailableG > A | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*14ANot AvailableG > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*14BNot AvailableG > A | C > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*14CNot AvailableG > A | T > C | C > T | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*14DNot AvailableG > A | C > T | G > A ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*14ENot AvailableG > A | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*14FNot AvailableG > A | T > C | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*14GNot AvailableG > A | C > T | A > G ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*17Not AvailableA > C ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Arylamine N-acetyltransferase 2NAT2*19Not AvailableC > T ADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash. Details
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of dose-related hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of dose-related hemolytic anemia. Details
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with 5-androstenedione.Experimental, Illicit
AbciximabSulfasalazine may increase the anticoagulant activities of Abciximab.Approved
AcebutololSulfasalazine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacAceclofenac may increase the nephrotoxic activities of Sulfasalazine.Approved
AcenocoumarolSulfasalazine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Sulfasalazine.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
AclarubicinSulfasalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneAdapalene may increase the nephrotoxic activities of Sulfasalazine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid.Approved
AliskirenSulfasalazine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololSulfasalazine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Sulfasalazine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Amcinonide.Approved
AmikacinSulfasalazine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSulfasalazine may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinSulfasalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodSulfasalazine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideHMPL-004 may increase the nephrotoxic activities of Sulfasalazine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Anecortave.Investigational
AnisodamineAnisodamine may increase the nephrotoxic activities of Sulfasalazine.Investigational
annamycinSulfasalazine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may increase the nephrotoxic activities of Sulfasalazine.Approved
Antithrombin III humanSulfasalazine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanSulfasalazine may increase the anticoagulant activities of Apixaban.Approved
ApocyninAcetovanillone may increase the nephrotoxic activities of Sulfasalazine.Investigational
ApramycinSulfasalazine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastApremilast may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
ArbekacinSulfasalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ardeparin.Approved, Withdrawn
ArgatrobanSulfasalazine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSulfasalazine may decrease the antihypertensive activities of Arotinolol.Approved
AtenololSulfasalazine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneAzapropazone may increase the nephrotoxic activities of Sulfasalazine.Withdrawn
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Sulfasalazine.Approved
AzelastineAzelastine may increase the nephrotoxic activities of Sulfasalazine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sulfasalazine.Approved
BalsalazideSulfasalazine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminSulfasalazine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSulfasalazine may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sulfasalazine.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulfasalazine.Approved
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Sulfasalazine.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Sulfasalazine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Betamethasone.Approved, Vet Approved
BetaxololSulfasalazine may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidBetulinic Acid may increase the nephrotoxic activities of Sulfasalazine.Investigational
BevantololSulfasalazine may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Sulfasalazine.Approved, Investigational
BisoprololSulfasalazine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSulfasalazine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSulfasalazine may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacBromfenac may increase the nephrotoxic activities of Sulfasalazine.Approved
BucillamineBucillamine may increase the nephrotoxic activities of Sulfasalazine.Investigational
BucindololSulfasalazine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Budesonide.Approved
BufuralolSulfasalazine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideSulfasalazine may decrease the diuretic activities of Bumetanide.Approved
BupranololSulfasalazine may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulfasalazine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sulfasalazine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Sulfasalazine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Sulfasalazine.Approved
CarprofenCarprofen may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved, Withdrawn
CarteololSulfasalazine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSulfasalazine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the nephrotoxic activities of Sulfasalazine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Celecoxib.Approved, Investigational
CeliprololSulfasalazine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Certoparin.Approved
ChloroquineChloroquine may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulfasalazine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateTrisalicylate-choline may increase the nephrotoxic activities of Sulfasalazine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulfasalazine.Approved
CinoxacinSulfasalazine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinSulfasalazine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidSulfasalazine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the nephrotoxic activities of Sulfasalazine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Sulfasalazine.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cortisone acetate.Approved
CurcuminCurcumin may increase the nephrotoxic activities of Sulfasalazine.Investigational
CyclosporineSulfasalazine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the nephrotoxic activities of Sulfasalazine.Investigational
Dabigatran etexilateSulfasalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dalteparin.Approved
DanaparoidSulfasalazine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSulfasalazine may increase the anticoagulant activities of Ym150.Investigational
DaunorubicinSulfasalazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Deferasirox.Approved, Investigational
DesirudinSulfasalazine may increase the anticoagulant activities of Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Sulfasalazine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfasalazine.Approved
DextranSulfasalazine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Sulfasalazine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Sulfasalazine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Sulfasalazine may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Sulfasalazine.Approved, Vet Approved
DiclofenacDiclofenac may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
DicoumarolSulfasalazine may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the nephrotoxic activities of Sulfasalazine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Sulfasalazine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sulfasalazine.Approved
DihydrostreptomycinSulfasalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Sulfasalazine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Sulfasalazine.Approved
DoxorubicinSulfasalazine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSulfasalazine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamDroxicam may increase the nephrotoxic activities of Sulfasalazine.Approved
DuvelisibDuvelisib may increase the nephrotoxic activities of Sulfasalazine.Investigational
E-6201E6201 may increase the nephrotoxic activities of Sulfasalazine.Investigational
EbselenEbselen may increase the nephrotoxic activities of Sulfasalazine.Investigational
Edetic AcidSulfasalazine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSulfasalazine may increase the anticoagulant activities of Edoxaban.Approved
EltrombopagThe serum concentration of Sulfasalazine can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Sulfasalazine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sulfasalazine.Approved
EnoxacinSulfasalazine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Enoxaparin.Approved
EpirizoleEpirizole may increase the nephrotoxic activities of Sulfasalazine.Approved
EpirubicinSulfasalazine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSulfasalazine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulfasalazine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulfasalazine.Approved
EquileninThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Equilin.Approved
EsmololSulfasalazine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Estrone sulfate.Approved
Etacrynic acidSulfasalazine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptEtanercept may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
Ethyl biscoumacetateSulfasalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the nephrotoxic activities of Sulfasalazine.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Sulfasalazine.Approved
exisulindexisulind may increase the nephrotoxic activities of Sulfasalazine.Investigational
FenbufenFenbufen may increase the nephrotoxic activities of Sulfasalazine.Approved
FenoprofenFenoprofen may increase the nephrotoxic activities of Sulfasalazine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Sulfasalazine.Vet Approved
FleroxacinSulfasalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Sulfasalazine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fludrocortisone.Approved
FluindioneSulfasalazine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSulfasalazine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flunisolide.Approved, Investigational
FlunixinFlunixin may increase the nephrotoxic activities of Sulfasalazine.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Sulfasalazine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flurandrenolide.Approved
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluticasone Propionate.Approved
Folic AcidThe serum concentration of Folic Acid can be decreased when it is combined with Sulfasalazine.Approved, Nutraceutical, Vet Approved
FondaparinuxSulfasalazine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSulfasalazine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Sulfasalazine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sulfasalazine.Approved
FramycetinSulfasalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSulfasalazine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateSulfasalazine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSulfasalazine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSulfasalazine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Sulfasalazine.Approved, Withdrawn
GemifloxacinSulfasalazine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSulfasalazine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSulfasalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASulfasalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinSulfasalazine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Sulfasalazine is combined with HE3286.Investigational
HeparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Heparin.Approved, Investigational
HigenamineHigenamine may increase the nephrotoxic activities of Sulfasalazine.Investigational
HydralazineSulfasalazine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulfasalazine.Approved
Hygromycin BSulfasalazine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibandronate.Approved, Investigational
IbuprofenIbuprofen may increase the nephrotoxic activities of Sulfasalazine.Approved
IbuproxamIbuproxam may increase the nephrotoxic activities of Sulfasalazine.Withdrawn
IcatibantIcatibant may increase the nephrotoxic activities of Sulfasalazine.Approved
IdarubicinSulfasalazine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxSulfasalazine may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulfasalazine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sulfasalazine.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulfasalazine.Approved
IndenololSulfasalazine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinIndomethacin may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
IndoprofenIndoprofen may increase the nephrotoxic activities of Sulfasalazine.Withdrawn
INNO-206Sulfasalazine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulfasalazine.Approved, Investigational
IsoxicamIsoxicam may increase the nephrotoxic activities of Sulfasalazine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Istaroxime.Investigational
KanamycinSulfasalazine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneKebuzone may increase the nephrotoxic activities of Sulfasalazine.Experimental
KetoprofenKetoprofen may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Sulfasalazine.Approved
KetorolacKetorolac may increase the nephrotoxic activities of Sulfasalazine.Approved
LabetalolSulfasalazine may decrease the antihypertensive activities of Labetalol.Approved
LandiololSulfasalazine may decrease the antihypertensive activities of Aop200704.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Sulfasalazine.Approved, Investigational
LeflunomideLeflunomide may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
LepirudinSulfasalazine may increase the anticoagulant activities of Lepirudin.Approved
LevobunololSulfasalazine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSulfasalazine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Sulfasalazine.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sulfasalazine.Approved, Investigational
LisofyllineLisofylline may increase the nephrotoxic activities of Sulfasalazine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Sulfasalazine.Approved
LomefloxacinSulfasalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamLornoxicam may increase the nephrotoxic activities of Sulfasalazine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Sulfasalazine.Approved
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Sulfasalazine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Sulfasalazine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Sulfasalazine.Vet Approved
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Sulfasalazine.Approved
MasoprocolMasoprocol may increase the nephrotoxic activities of Sulfasalazine.Approved
ME-609The risk or severity of adverse effects can be increased when Sulfasalazine is combined with ME-609.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Medrysone.Approved
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Sulfasalazine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Melengestrol.Vet Approved
MeloxicamMeloxicam may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Sulfasalazine.Approved
MesalazineMesalazine may increase the nephrotoxic activities of Sulfasalazine.Approved
MetamizoleMetamizole may increase the nephrotoxic activities of Sulfasalazine.Withdrawn
MethotrexateSulfasalazine may increase the hepatotoxic activities of Methotrexate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSulfasalazine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine.Approved
MetoprololSulfasalazine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSulfasalazine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Sulfasalazine.Approved
MizoribineMizoribine may increase the nephrotoxic activities of Sulfasalazine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulfasalazine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Sulfasalazine.Approved
MoxifloxacinSulfasalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Sulfasalazine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nabumetone.Approved
NadololSulfasalazine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nadroparin.Approved
NafamostatNafamostat may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
NaftifineNaftifine may increase the nephrotoxic activities of Sulfasalazine.Approved
Nalidixic AcidSulfasalazine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenNaproxen may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Sulfasalazine is combined with NCX 1022.Investigational
NeamineSulfasalazine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinSulfasalazine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSulfasalazine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacNepafenac may increase the nephrotoxic activities of Sulfasalazine.Approved
NetilmicinSulfasalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Sulfasalazine.Approved
NimesulideNimesulide may increase the nephrotoxic activities of Sulfasalazine.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the nephrotoxic activities of Sulfasalazine.Investigational
NorfloxacinSulfasalazine may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinSulfasalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinThe serum concentration of Anvirzel can be decreased when it is combined with Sulfasalazine.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sulfasalazine.Approved, Investigational
OlopatadineOlopatadine may increase the nephrotoxic activities of Sulfasalazine.Approved
OlsalazineSulfasalazine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Sulfasalazine.Investigational
OrgoteinOrgotein may increase the nephrotoxic activities of Sulfasalazine.Vet Approved
OtamixabanSulfasalazine may increase the anticoagulant activities of Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Sulfasalazine.Approved
OxaprozinOxaprozin may increase the nephrotoxic activities of Sulfasalazine.Approved
OxprenololSulfasalazine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Sulfasalazine.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Parnaparin.Approved
ParomomycinSulfasalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sulfasalazine.Approved
PazufloxacinSulfasalazine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSulfasalazine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSulfasalazine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateSulfasalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Sulfasalazine.Approved
PhenindioneSulfasalazine may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonSulfasalazine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
PindololSulfasalazine may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinSulfasalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSulfasalazine may decrease the diuretic activities of Piretanide.Experimental
PirfenidonePirfenidone may increase the nephrotoxic activities of Sulfasalazine.Investigational
PiroxicamPiroxicam may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
PlicamycinSulfasalazine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Sulfasalazine.Approved
PractololSulfasalazine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Sulfasalazine.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Sulfasalazine can be increased when it is combined with Probenecid.Approved
PropacetamolPropacetamol may increase the nephrotoxic activities of Sulfasalazine.Approved
PropranololSulfasalazine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Sulfasalazine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Sulfasalazine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Sulfasalazine.Vet Approved
Protein CSulfasalazine may increase the anticoagulant activities of Protein C.Approved
Protein S humanSulfasalazine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSulfasalazine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSulfasalazine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299PTC299 may increase the nephrotoxic activities of Sulfasalazine.Investigational
PuromycinSulfasalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulfasalazine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Sulfasalazine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sulfasalazine.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulfasalazine.Approved
ResveratrolResveratrol may increase the nephrotoxic activities of Sulfasalazine.Experimental, Investigational
ReviparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Reviparin.Approved
RibostamycinSulfasalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Risedronate.Approved, Investigational
RivaroxabanSulfasalazine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe serum concentration of Sulfasalazine can be increased when it is combined with Rolapitant.Approved
RosoxacinSulfasalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Sulfasalazine.Approved
SalicylamideSalicylamide may increase the nephrotoxic activities of Sulfasalazine.Approved
Salicylic acidSalicylic acid may increase the nephrotoxic activities of Sulfasalazine.Approved, Vet Approved
SalsalateSalsalate may increase the nephrotoxic activities of Sulfasalazine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulfasalazine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Sulfasalazine.Investigational
SeratrodastSeratrodast may increase the nephrotoxic activities of Sulfasalazine.Approved
SisomicinSulfasalazine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolSulfasalazine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSulfasalazine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSulfasalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinSulfasalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Sulfasalazine.Approved
SpironolactoneSulfasalazine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501SRT501 may increase the nephrotoxic activities of Sulfasalazine.Investigational
StreptomycinSulfasalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSulfasalazine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulindacSulindac may increase the nephrotoxic activities of Sulfasalazine.Approved
SulodexideSulfasalazine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Sulfasalazine.Investigational
SuprofenSuprofen may increase the nephrotoxic activities of Sulfasalazine.Approved, Withdrawn
TacrolimusSulfasalazine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Sulfasalazine.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Sulfasalazine.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Sulfasalazine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulfasalazine.Approved, Investigational
TemafloxacinSulfasalazine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Sulfasalazine.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may increase the nephrotoxic activities of Sulfasalazine.Approved
TepoxalinTepoxalin may increase the nephrotoxic activities of Sulfasalazine.Vet Approved
TeriflunomideThe serum concentration of Sulfasalazine can be increased when it is combined with Teriflunomide.Approved
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Sulfasalazine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tiludronate.Approved, Vet Approved
TimololSulfasalazine may decrease the antihypertensive activities of Timolol.Approved
TinoridineTinoridine may increase the nephrotoxic activities of Sulfasalazine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tinzaparin.Approved
TioguanineThe metabolism of Tioguanine can be decreased when combined with Sulfasalazine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tixocortol.Approved
TobramycinSulfasalazine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Sulfasalazine.Approved
TolmetinTolmetin may increase the nephrotoxic activities of Sulfasalazine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sulfasalazine.Approved, Investigational
TorasemideSulfasalazine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sulfasalazine.Approved
TranilastTranilast may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulfasalazine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulfasalazine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSulfasalazine may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
TrovafloxacinSulfasalazine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Sulfasalazine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinSulfasalazine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulfasalazine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Sulfasalazine.Approved
WarfarinSulfasalazine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSulfasalazine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Sulfasalazine.Approved
ZileutonZileuton may increase the nephrotoxic activities of Sulfasalazine.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zoledronic acid.Approved
ZomepiracZomepirac may increase the nephrotoxic activities of Sulfasalazine.Withdrawn
ZorubicinSulfasalazine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • May take Vitamin D.
  • Take with a full glass of water No iron, zinc or fluoride within 2 hours of taking this medication.
  • Take with food.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA07EC01 — SulfasalazineG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 08:12.20
PDB EntriesNot Available
FDA labelDownload (796 KB)
MSDSDownload (72.8 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedBasic ScienceAdministration, Oral / Magnetic Resonance Imaging (MRI) / Pharmacokinetics1
1CompletedBasic ScienceIntestinal Obstruction2
1CompletedBasic ScienceProphylaxis of acute chemotherapy induced nausea and vomiting1
2RecruitingTreatmentAnkylosing Spondylitis (AS)1
2RecruitingTreatmentPainful Neuropathy1
2RecruitingTreatmentRheumatoid Arthritis1
2Unknown StatusTreatmentModerate to Severe Active Axial Spondyloarthritis1
2, 3Unknown StatusTreatmentEarly Ankylosing Spondylitis1
3Active Not RecruitingSupportive CareDiarrhea / Gastrointestinal Complications / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentRheumatoid Arthritis5
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4CompletedTreatmentAnkylosing Spondylitis (AS)1
4CompletedTreatmentRheumatoid Arthritis2
4Not Yet RecruitingTreatmentAnkylosing Spondylitis (AS)1
4Not Yet RecruitingTreatmentCardiovascular Risk Factors / Endothelial Dysfunction / Rheumatoid Arthritis / Stiffness, Aortic1
4RecruitingTreatmentRheumatoid Arthritis3
4TerminatedTreatmentArthritis, Juvenile Rheumatoid1
Not AvailableCompletedBasic ScienceCoronary Artery Disease1
Not AvailableCompletedTreatmentAlcohol Dependence1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableCompletedTreatmentRheumatoid Arthritis1
Not AvailableRecruitingTreatmentRecurrence (Disease Attribute)1
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Solvay pharmaceuticals
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Superpharm corp
Packagers
Dosage forms
FormRouteStrength
Tablet, delayed releaseOral500 mg
SuspensionRectal3 g
EnemaRectal3 g
TabletOral500 mg
TabletOral500 mg/1
Tablet, delayed releaseOral500 mg/1
Prices
Unit descriptionCostUnit
Sulfasalazine powder2.14USD g
Azulfidine EN-tabs 500 mg Enteric Coated Tabs0.73USD tab
Azulfidine entab 500 mg0.69USD tablet
Azulfidine 500 mg tablet0.59USD tablet
Salazopyrin En-Tabs 500 mg Enteric-Coated Tablet0.45USD tablet
Sulfasalazine 500 mg Enteric Coated Tabs0.4USD tab
Pms-Sulfasalazine 500 mg Enteric-Coated Tablet0.34USD tablet
Salazopyrin 500 mg Tablet0.28USD tablet
Sulfasalazine 500 mg tablet0.25USD tablet
Sulfazine 500 mg tablet0.25USD tablet
Pms-Sulfasalazine 500 mg Tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)220 dec °CPhysProp
logP2.5Not Available
Caco2 permeability-6.33ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0464 mg/mLALOGPS
logP2.92ALOGPS
logP3.94ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)3.3ChemAxon
pKa (Strongest Basic)2.4ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area141.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.6 m3·mol-1ChemAxon
Polarizability39.69 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.7294
Caco-2 permeable-0.6893
P-glycoprotein substrateNon-substrate0.8405
P-glycoprotein inhibitor INon-inhibitor0.9096
P-glycoprotein inhibitor IINon-inhibitor0.853
Renal organic cation transporterNon-inhibitor0.8956
CYP450 2C9 substrateNon-substrate0.6445
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.923
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8895
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6468
BiodegradationNot ready biodegradable0.9472
Rat acute toxicity1.4383 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.939
hERG inhibition (predictor II)Non-inhibitor0.821
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0002-0239100000-5bf223e6e250eb77105aView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a benzene ring.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassAzobenzenes
Direct ParentAzobenzenes
Alternative ParentsSalicylic acids / Benzenesulfonamides / Benzenesulfonyl compounds / Benzoic acids / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Pyridines and derivatives / Organosulfonamides / Imidolactams / Vinylogous acids
SubstituentsAzobenzene / Benzenesulfonamide / Hydroxybenzoic acid / Salicylic acid or derivatives / Salicylic acid / Benzoic acid or derivatives / Benzoic acid / Benzenesulfonyl group / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorssulfonamide, azobenzenes, pyridines (CHEBI:9334 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Uniprot Name:
Arachidonate 5-lipoxygenase
Molecular Weight:
77982.595 Da
References
  1. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82. [PubMed:2882965 ]
  2. Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51. [PubMed:6428914 ]
  3. Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2. [PubMed:6131674 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Uniprot Name:
Prostaglandin G/H synthase 2
Molecular Weight:
68995.625 Da
References
  1. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8. [PubMed:14742690 ]
  2. Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94. [PubMed:12463455 ]
  3. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19. [PubMed:16855178 ]
  4. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6. [PubMed:12208114 ]
  5. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Uniprot Name:
Prostaglandin G/H synthase 1
Molecular Weight:
68685.82 Da
References
  1. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Uniprot Name:
Peroxisome proliferator-activated receptor gamma
Molecular Weight:
57619.58 Da
References
  1. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11. [PubMed:15824083 ]
  2. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. doi: 10.1093/carcin/bgn118. Epub 2008 Jun 9. [PubMed:18544567 ]
  3. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [PubMed:18077625 ]
  4. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [PubMed:16939423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications...
Gene Name:
CHUK
Uniprot ID:
O15111
Uniprot Name:
Inhibitor of nuclear factor kappa-B kinase subunit alpha
Molecular Weight:
84638.88 Da
References
  1. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These mo...
Gene Name:
IKBKB
Uniprot ID:
O14920
Uniprot Name:
Inhibitor of nuclear factor kappa-B kinase subunit beta
Molecular Weight:
86563.245 Da
References
  1. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Cystine:glutamate antiporter activity
Specific Function:
Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.
Gene Name:
SLC7A11
Uniprot ID:
Q9UPY5
Uniprot Name:
Cystine/glutamate transporter
Molecular Weight:
55422.44 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gout PW, Buckley AR, Simms CR, Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia. 2001 Oct;15(10):1633-40. [PubMed:11587223 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a major role in ketone body metabolism.
Gene Name:
ACAT1
Uniprot ID:
P24752
Uniprot Name:
Acetyl-CoA acetyltransferase, mitochondrial
Molecular Weight:
45199.2 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Faison LD, White HL: Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase. Prostaglandins. 1992 Sep;44(3):245-9. [PubMed:1357724 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thromboxane-a synthase activity
Specific Function:
Not Available
Gene Name:
TBXAS1
Uniprot ID:
P24557
Uniprot Name:
Thromboxane-A synthase
Molecular Weight:
60517.69 Da
References
  1. Stenson WF, Lobos E: Inhibition of platelet thromboxane synthetase by sulfasalazine. Biochem Pharmacol. 1983 Jul 15;32(14):2205-9. [PubMed:6135423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor binding
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
Gene Name:
PLA2G1B
Uniprot ID:
P04054
Uniprot Name:
Phospholipase A2
Molecular Weight:
16359.535 Da
References
  1. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Uniprot Name:
Cytochrome P450 3A5
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Uniprot Name:
ATP-binding cassette sub-family G member 2
Molecular Weight:
72313.47 Da
References
  1. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13. [PubMed:20071452 ]
  2. Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7. doi: 10.1007/s11095-008-9735-8. Epub 2008 Oct 9. [PubMed:18841445 ]
  3. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Uniprot Name:
Canalicular multispecific organic anion transporter 1
Molecular Weight:
174205.64 Da
References
  1. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Methotrexate transporter activity
Specific Function:
Has been shown to act both as an intestinal proton-coupled high-affinity folate transporter and as an intestinal heme transporter which mediates heme uptake from the gut lumen into duodenal epithelial cells. The iron is then released from heme and may be transported into the bloodstream. Dietary heme iron is an important nutritional source of iron. Shows a higher affinity for folate than heme.
Gene Name:
SLC46A1
Uniprot ID:
Q96NT5
Uniprot Name:
Proton-coupled folate transporter
Molecular Weight:
49770.04 Da
References
  1. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, Yuasa H: Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007 Aug;322(2):469-76. Epub 2007 May 2. [PubMed:17475902 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:32